期刊
CURRENT ONCOLOGY REPORTS
卷 16, 期 1, 页码 -出版社
SPRINGER
DOI: 10.1007/s11912-013-0359-8
关键词
Breast cancer; Trastuzumab; Pertuzumab; Trastuzumab emtansine; Trastuzumab-DM1; HER2-positive; Lapatinib; Neratinib; Afatinib; MM-302; Everolimus
类别
资金
- Genentech
Overexpression of human epidermal growth factor occurs in approximately 20-25 % of invasive breast cancers. This subtype of breast cancer has been associated with poor clinical outcomes. The development of trastuzumab, a humanized monoclonal antibody that binds to the extracellular domain of human epidermal growth factor receptor 2 (HER2), revolutionized outcomes of patients with HER2-positive breast cancer; however, many patients with HER2-positive metastatic breast cancer eventually become resistant to it. Several newer anti-HER2 agents have been developed, including lapatinib, pertuzumab, and trastuzumab emtansine. These exciting advances in drug development for HER2-positive breast cancer have also led to many challenges, including how to optimally sequence and combine HER2-targeted agents.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据